Adam Fischbaum brings more than 20 years of professional investment experience as financial advisor and portfolio manager. Affiliated with an NYSE-member firm, he specializes in value, income and macro thematic investing. Adam is also a contributing editor for Yieldpig.com and his work is published frequently on TheStreet.com, BusinessInsdider.com, as well, Seeking Alpha and TalkMarkets.com. He currently holds a Series 7, 63, 65, and 31 license. Adam lives on the Gulf Coast with his wife and two sons. When he’s not running money or writing about it, he enjoys hunting and fishing.  

Analyst Articles

There’s something more to insurance giant Aflac (NYSE: AFL) than just the funny (and wildly successful) duck mascot. Weighing in at a hefty $26.8 billion market cap, Aflac (originally the American Family Life Assurance Co.) writes supplemental health and life insurance in the United States and Japan. Read More

I remember how nutty investors were for shares of the big pharmaceutical companies 15 years ago. Pfizer (NYSE: PFE) had just put the spark back into middle-aged marriages, thanks to its failed blood pressure med that had a surprisingly pleasant side affect. Other companies followed suit with similar… Read More

During their baby phase, investors are totally in love with them. The newborn is absolutely perfect... Read More

During their baby phase, investors are totally in love with them. The newborn is absolutely perfect and the stockholders will coo and brag, and throw money at their pride and joy regardless of price.... Read More

The capital markets are enjoying a bit of a renaissance in maniacal, pre-IPO valuation for Internet companies, more specifically, social networking businesses. The 900-pound gorilla of social networking, Facebook, has an estimated value of $50 billion or so thanks in part to the fact it decided to be Goldman… Read More